Notice: The ASA website will be unavailable beginning Thursday, May 17 from 4 p.m. until noon (CDT) on May 18 due to system maintenance.

>

WEBINARS

RSS
>

MEETINGS / EVENTS

RSS

October 13 - 17 2012, 12:00 AM - 12:00 AM

ANESTHESIOLOGY 2012

>

FDA MEDWATCH ALERTS

RSS

May 16, 2012

Hydromorphone Hydrochloride Recall

Summary:

Hydromorphone Hydrochloride Recall

April 18, 2012

Morphine Sulfate Injection USP, 4 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject by Hospira, Inc: Recall - May Contain More Than Intended Fill Volume

Summary:

Customer report of two Carpujects syringes containing more than the 1 mL labeled fill volume. Opioid pain medications such as morphine have life-threatening consequences if overdosed. Those consequences can include respiratory depression (slowed breathing or suspension of breathing), and low blood pressure.

March 05, 2012

Cardiac Science Powerheart, CardioVive, CardioLife; GE Responder and Responder Pro; and Nihon-Kohden Automated External Defibrillators (AEDs): Class I Recall - Defective Component

Summary: FDA notified healthcare professionals and medical care organizations of the Class 1 recall of the listed AEDs which contain a component that may fail unexpectedly due to a defect. If the component were to fail during a rescue attempt, the AED may not deliver defibrillation therapy, causing serious adverse health consequences, including death. The unit’s self test may not detect the failure or impending failure of the component.

>

ASA FEATURED PRODUCT

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-12CE

... Read more »

Single Copies, Member Price: $300

ASA Responds to Federal Trade Commission's Proposed Statement on ACO Antitrust Enforcement

Tuesday, May 31, 2011

In conjunction with the release of the Centers for Medicare and Medicaid Services (CMS) proposed rule on Accountable Care Organizations (ACOs), the Federal Trade Commission (FTC) released a proposed statement of antitrust enforcement policy regarding ACOs participating in the Medicare Shared Savings Program. The ASA recently submitted a letter to the FTC in response to the proposed statement.  Next week, the ASA will submit comprehensive comments to CMS on the proposed ACO rule.

In the letter to the FTC, the ASA states it is in general agreement with comments made by the American Medical Association. The ASA letter goes on to detail how the proposed statement would impact anesthesiologists specifically.   

ASA concludes the letter by stating: “To ensure the success of the Shared Savings Program, it is critical for CMS and the FTC/DOJ to develop a Shared Savings Program and associated antitrust clearance process that enables the majority of physicians to develop, lead and actively participate in ACOs.  While ASA supports the application of the rule of reason to ACOs, we have serious reservations about the market power implications and their impact on anesthesiologists.“

Click here to read the letter submitted by ASA.

Click here to read the FTC proposed statement.

Click here for the latest information on the work ASA is doing regarding ACOs.

 

 

« Back to Washington Alerts